Anticoagulants Market
Anticoagulants Market Analysis By Drug Class (Factor X Inhibitor (NOAC/DOAC) Anticoagulants, Heparin Anticoagulants, Direct Thrombin Inhibitor Anticoagulants, Vitamin K Antagonist Anticoagulants), By Route of Administration, By Indication - Global Market Insights 2021 to 2031
Analysis of Anticoagulants market covering 30 + countries including analysis of US, Canada, UK, Germany, France, Nordics, GCC countries, Japan, Korea and many more
Anticoagulants Market Outlook (2021 to 2031)
The sales of anticoagulant are expected to reach US$ 30 Billion by the end of 2021. As per the study, demand will continue rising, expanding over 2x to be valued at US$ 65 Billion by the end of the 2021-2031 assessment period.
Players are increasingly utilizing internet sales channels to extend their reach while requiring less financial commitment. On the demand side, the rising incidence of heart attacks, owing to patients' unhealthy lifestyle choices, is expected to expand the patient pool for the anticoagulants market over the forecast period.
Know thy Competitors
Competitive landscape highlights only certain players
Complete list available upon request
Anticoagulants Consumption Analysis 2016-2020 Vs Outlook 2021-2031
Sales of anticoagulants expanded at a CAGR of 5% across the historical period ranging from 2016 to 2020. Demand for anticoagulants has increased significantly in emerging nations, owing to the financial assistance provided by central governments to renovate healthcare facilities and improve service quality.
Leading firms are utilizing research and development operations to increase the number of pipeline medicines, recognizing the anticoagulants market's strong growth possibilities. The Global Anticoagulants Market is estimated to be worth US$ 65 Billion by 2031, expanding at an 8.04 % CAGR during the forecast period.
More Insights, Lesser Cost (-50% off)
Insights on import/export production,
pricing analysis, and more – Only @ Fact.MR
Surging Atrial Fibrillation Cases Spurring Anticoagulants Consumption?
The most common heart arrhythmia is atrial fibrillation. It is projected that 6-12 million individuals in the United States will have this disease by 2050, and 17.9 million people in Europe will have it by 2060. Atrial fibrillation is a substantial risk factor for ischemic stroke, causing a large economic burden as well as morbidity and death.
As per the National Center for Biotechnology Information, during 2017, over 3 million new instances of atrial fibrillation were detected globally. The 2017 estimated incidence rate (403/million inhabitants) was 31% higher than the 1997 corresponding incidence. The global prevalence of atrial fibrillation is 37,574 million instances, and it has grown by 33% in the past two decades.
The biggest burden is observed in nations with a high socio-demographic index; however the most recent growth occurred in countries with a moderate socio-demographic index. According to estimates, the absolute burden of atrial fibrillation may grow by more than 60% by 2050. Hence, all these factors contribute to the market growth during the forecast period.
Country Wise Analysis
How do Anticoagulants Growth Prospects Appear in the U.S?
U.S. accounted for the biggest proportion of anticoagulants in 2020, owing to increased knowledge about the therapeutic uses of anticoagulants in disease management and the country's rising obesity prevalence. Furthermore, it has the highest obesity prevalence in the world.
According to the Centers for Disease Control and Prevention (CDC), the obesity prevalence in the United States was 42.4% in 2017–2018. Obesity in the United States rose from 30.5% to 42.4% between 1999 and 2018. Based on aforementioned trends, the U.S market is expected to surge at a CAGR of 7.5% until 2031.
How big is the Anticoagulants Industry in Japan?
According to the World Bank, a projected 28% of Japan's total population is over 65 in 2020, with that figure predicted to increase to 40% by 2060. As a result, blood thinners such as Xarelto are widely recommended to the elderly for the treatment and prevention of blood clots. A market share worth 45% is expected for the Japanese market.
With an ageing population, demand for anticoagulants is strong, as they require surgical interventions for numerous chronic conditions. Geriatrics are more likely to have diseases such as venous thromboembolism, atrial fibrillation, and knee and hip replacement operations, increasing their risk of forming blood clots and, as a result, heart attacks and strokes.
Why is China an Emerging Market for Anticoagulants?
China is anticipated to expand at the highest rate throughout the projection period, clocking a CAGR exceeding 8% until 2031. High prevalence rate of cardiovascular diseases is spurring surgeries across the East Asian giant, paving way for high usage of anticoagulants.
According to the Lancet, nearly 4 million deaths occur due to CVDs in China annually. In an effort to mitigate the risk and reduce this burden, healthcare practitioners are advocating advanced surgical interventions. However, the risk of embolism arising from such surgeries has also increased, prompting usage of anticoagulants.
Category Wise Insights
Why the Preference for NOAC/DOAC Factor X Inhibitors?
By drug class, NOAC/DOAC factor X inhibitors accounted for over 50% of total anticoagulants demand in 2019. This is attributed to increased NOAC uptake in poorer nations, as well as increased usage of NOACs over warfarin.
Furthermore, NOACs including betrixaban, rivaroxaban, apixaban, dabigatran, and edoxaban are used to treat and prevent atrial fibrillation/myocardial infarction, pulmonary embolism, and deep vein thrombosis (DVT). They possess numerous advantages over warfarin, including minimal dietary restrictions, fast start effect, predictable pharmacokinetic action, less drug and food interaction, and a shorter half-life.
Why are Hospital Pharmacies Primary Anticoagulants Distributors?
Hospital pharmacies are expected to account for 49.2% revenue share. This is because hospitals are the major sites for the diagnosis and treatment of many forms of bleeding problems.
As the volume of surgeries for various chronic conditions increase, episodes of embolisms post-surgery are increasing manifold. As a result, doctors highly recommend use of anticoagulants to prevent further complications in the patient.
Competitive Landscape
The anticoagulants landscape is competitive and fragmented, with numerous significant competitors. As a tool to increase anticoagulant exposure, players in the anticoagulants industry are stepping forward to carry the financial burden of individuals through patient-assistance programmes.
- In August 2020, Bristol-Myers Squibb, in alliance with Pfizer, announced that the U.S District Court upheld their composition of matter (COP) patent (US 6,967,208) and formulation patent (US 9,326,945) covering their Eliquis® Apixaban anticoagulants.
- Likewise, in November 2020, Boehringer Ingelheim received approval from the European Medicine Agency’s Committee for Medicinal Products for Human Use (CHMP) for the use of Pradaxa® (dabigatran etexilate) for treating venous thromboembolic events and preventing its recurrence in pediatric patients below 18 years
Report Scope
Report Attributes |
Details |
|
The market size value in 2021 |
USD 30 Billion |
|
Market forecast value in 2031 |
USD 65 Billion |
|
Growth Rate |
CAGR of 8.04% from 2021 to 2031 |
| Forecast Period | 2021-2031 |
| Historical Data Available for | 2016-2020 |
|
Key Market Segments Covered |
|
|
Key Companies Profiled |
|
Key Segments Covered
-
By Drug Class
- Factor X Inhibitor (NOAC/DOAC) Anticoagulants
- Heparin Anticoagulants
- Direct Thrombin Inhibitor Anticoagulants
- Vitamin K Antagonist Anticoagulants
-
By Indication
- Deep Vein Thrombosis
- Pulmonary Embolism
- Atrial Fibrillation & Heart Attack
- Other Indications
-
By Route of Administration
- Oral Anticoagulants
- Injectable Anticoagulants
-
By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
-
By Region
- North America
- Latin America
- Europe
- Asia Pacific
- Middle East & Africa
Table of Content
1. Preface 1.1. Market Definition and Scope 1.2. Market Segmentation 1.3. Key Research Objectives 1.4. Research Highlights 2. Assumptions and Research Methodology 3. Executive Summary: Global Anticoagulants Market 4. Market Overview 4.1. Introduction 4.1.1. Route of Administration Definition 4.1.2. Industry Evolution / Developments 4.2. Overview 4.3. Market Dynamics 4.3.1. Drivers 4.3.2. Restraints 4.3.3. Opportunities 4.3.4. Market Trends 4.4. Global Anticoagulants market analysis and Forecast, 2016–2031 4.5. Porter’s Five Force Analysis 5. Market Outlook 5.1. Key Mergers & Acquisitions 6. Global Anticoagulants Market Analysis and Forecast, by Route of Administration 6.1. Introduction & Definition 6.2. Key Findings / Developments 6.3. Market Value Forecast, by Route of Administration, 2016–2031 6.3.1. Oral 6.3.2. Injectable 6.4. Market Attractiveness, by Route of Administration 7. Global Anticoagulants Market Analysis and Forecast, by Drug Class 7.1. Introduction & Definition 7.2. Key Findings / Developments 7.3. Market Value Forecast, by Drug Class, 2016–2031 7.3.1. Factor XA Inhibitors (NOAC/DOAC) 7.3.2. Heparins 7.3.3. Direct Thrombin Inhibitors 7.3.4. Vitamin K Antagonists 7.4. Market Attractiveness, by Drug Class 8. Global Anticoagulants Market Analysis and Forecast, by Indication 8.1. Introduction & Definition 8.2. Key Findings / Developments 8.3. Market Value Forecast, by Distribution Channel, 2016–2031 8.3.1. Deep Vein Thrombosis 8.3.2. Pulmonary Embolism 8.3.3. Atrial Fibrillation & Heart Attack 8.3.4. Others 8.4. Market Attractiveness, by Distribution Channel 9. Global Anticoagulants Market Analysis and Forecast, by Distribution Channel 9.1. Introduction & Definition 9.2. Key Findings / Developments 9.3. Market Value Forecast, by Distribution Channel, 2016–2031 9.3.1. Hospital Pharmacies 9.3.2. Retail Pharmacies 9.3.3. Online Pharmacies 9.4. Market Attractiveness, by Distribution Channel 10. Global Anticoagulants Market Analysis and Forecast, by Region 10.1. Key Findings 10.2. Market Value Forecast, by Region 10.2.1. North America 10.2.2. Europe 10.2.3. Asia Pacific 10.2.4. Latin America 10.2.5. Middle East & Africa 10.3. Market Attractiveness, by Region 11. North America Anticoagulants Market Analysis and Forecast 11.1. Introduction 11.1.1. Key Findings 11.2. Market Value Forecast, by Route of Administration, 2016–2031 11.2.1. Oral 11.2.2. Injectables 11.3. Market Value Forecast, by Drug Class, 2016–2031 11.3.1. Factor XA Inhibitors (NOAC/DOAC) 11.3.2. Heparins 11.3.3. Direct Thrombin Inhibitors 11.3.4. Vitamin K Antagonists 11.4. Market Value Forecast, by Distribution Channel, 2016–2031 11.4.1. Deep Vein Thrombosis 11.4.2. Pulmonary Embolism 11.4.3. Atrial Fibrillation & Heart Attack 11.4.4. Others 11.5. Market Value Forecast, by Distribution Channel, 2016–2031 11.5.1. Hospital Pharmacies 11.5.2. Retail Pharmacies 11.5.3. Online Pharmacies 11.6. Market Value Forecast, by Country, 2016–2031 11.6.1. U.S. 11.6.2. Canada 11.7. Market Attractiveness Analysis 11.7.1. By Route of Administration 11.7.2. By Drug Class 11.7.3. By Indication 11.7.4. By Distribution Channel 11.7.5. By Country 12. Europe Anticoagulants Market Analysis and Forecast 12.1. Introduction 12.1.1. Key Findings 12.2. Market Value Forecast, by Route of Administration, 2016–2031 12.2.1. Oral 12.2.2. Injectables 12.3. Market Value Forecast, by Drug Class, 2016–2031 12.3.1. Factor XA Inhibitors (NOAC/DOAC) 12.3.2. Heparins 12.3.3. Direct Thrombin Inhibitors 12.3.4. Vitamin K Antagonists 12.4. Market Value Forecast, by Distribution Channel, 2016–2031 12.4.1. Deep Vein Thrombosis 12.4.2. Pulmonary Embolism 12.4.3. Atrial Fibrillation & Heart Attack 12.4.4. Others 12.5. Market Value Forecast, by Distribution Channel, 2016–2031 12.5.1. Hospital Pharmacies 12.5.2. Retail Pharmacies 12.5.3. Online Pharmacies 12.6. Market Value Forecast, by Country/Sub-region, 2016–2031 12.6.1. Germany 12.6.2. U.K. 12.6.3. France 12.6.4. Italy 12.6.5. Spain 12.6.6. Rest of Europe 12.7. Market Attractiveness Analysis 12.7.1. By Route of Administration 12.7.2. By Drug Class 12.7.3. By Indication 12.7.4. By Distribution Channel 12.7.5. By Country/Sub-Region 13. Asia Pacific Anticoagulants Market Analysis and Forecast 13.1. Introduction 13.1.1. Key Findings 13.2. Market Value Forecast, by Route of Administration, 2016–2031 13.2.1. Oral 13.2.2. Injectables 13.3. Market Value Forecast, by Drug Class, 2016–2031 13.3.1. Factor XA Inhibitors (NOAC/DOAC) 13.3.2. Heparins 13.3.3. Direct Thrombin Inhibitors 13.3.4. Vitamin K Antagonists 13.4. Market Value Forecast, by Distribution Channel, 2016–2031 13.4.1. Deep Vein Thrombosis 13.4.2. Pulmonary Embolism 13.4.3. Atrial Fibrillation & Heart Attack 13.4.4. Others 13.5. Market Value Forecast, by Distribution Channel, 2016–2031 13.5.1. Hospital Pharmacies 13.5.2. Retail Pharmacies 13.5.3. Online Pharmacies 13.6. Market Value Forecast, by Country/Sub-region, 2016–2031 13.6.1. Japan 13.6.2. China 13.6.3. India 13.6.4. Australia & New Zealand 13.6.5. Rest of Asia Pacific 13.7. Market Attractiveness Analysis 13.7.1. By Route of Administration 13.7.2. By Drug Class 13.7.3. By Indication 13.7.4. By Distribution Channel 13.7.5. By Country/Sub-Region 14. Latin America Anticoagulants Market Analysis and Forecast 14.1. Introduction 14.1.1. Key Findings 14.2. Market Value Forecast, by Route of Administration, 2016–2031 14.2.1. Oral 14.2.2. Injectables 14.3. Market Value Forecast, by Drug Class, 2016–2031 14.3.1. Factor XA Inhibitors (NOAC/DOAC) 14.3.2. Heparins 14.3.3. Direct Thrombin Inhibitors 14.3.4. Vitamin K Antagonists 14.4. Market Value Forecast, by Distribution Channel, 2016–2031 14.4.1. Deep Vein Thrombosis 14.4.2. Pulmonary Embolism 14.4.3. Atrial Fibrillation & Heart Attack 14.4.4. Others 14.5. Market Value Forecast, by Distribution Channel, 2016–2031 14.5.1. Hospital Pharmacies 14.5.2. Retail Pharmacies 14.5.3. Online Pharmacies 14.6. Market Value Forecast, by Country/Sub-region, 2016–2031 14.6.1. Brazil 14.6.2. Mexico 14.6.3. Rest of Latin America 14.7. Market Attractiveness Analysis 14.7.1. By Route of Administration 14.7.2. By Drug Class 14.7.3. By Indication 14.7.4. By Distribution Channel 14.7.5. By Country/Sub-Region 15. Middle East & Africa Anticoagulants Market Analysis and Forecast 15.1. Introduction 15.1.1. Key Findings 15.2. Market Value Forecast, by Route of Administration, 2016–2031 15.2.1. Oral 15.2.2. Injectables 15.3. Market Value Forecast, by Drug Class, 2016–2031 15.3.1. Factor XA Inhibitors (NOAC/DOAC) 15.3.2. Heparins 15.3.3. Direct Thrombin Inhibitors 15.3.4. Vitamin K Antagonists 15.4. Market Value Forecast, by Distribution Channel, 2016–2031 15.4.1. Deep Vein Thrombosis 15.4.2. Pulmonary Embolism 15.4.3. Atrial Fibrillation & Heart Attack 15.4.4. Others 15.5. Market Value Forecast, by Distribution Channel, 2016–2031 15.5.1. Hospital Pharmacies 15.5.2. Retail Pharmacies 15.5.3. Online Pharmacies 15.6. Market Value Forecast, by Country/Sub-region, 2016–2031 15.6.1. GCC Countries 15.6.2. Israel 15.6.3. South Africa 15.6.4. Rest of Middle East & Africa 15.7. Market Attractiveness Analysis 15.7.1. By Route of Administration 15.7.2. By Drug Class 15.7.3. By Distribution Channel 15.7.4. By Indication 15.7.5. By Country/Sub-Region 16. Competition Landscape 16.1. Market Player - Competition Matrix 16.2. Market Share Analysis, by Company (2017) 16.3. Company Profiles 16.4. Bayer AG 16.4.1. Company Overview (HQ, Business Segments, Employee Strength) 16.4.2. Financial Overview 16.4.3. Product Portfolio 16.4.4. SWOT Analysis 16.4.5. Strategic Overview 16.5. Boehringer Ingelheim International GmbH 16.5.1. Company Overview (HQ, Business Segments, Employee Strength) 16.5.2. Financial Overview 16.5.3. Product Portfolio 16.5.4. SWOT Analysis 16.5.5. Strategic Overview 16.6. Bristol-Myers Squibb Company 16.6.1. Company Overview (HQ, Business Segments, Employee Strength) 16.6.2. Financial Overview 16.6.3. Product Portfolio 16.6.4. SWOT Analysis 16.6.5. Strategic Overview 16.7. Daiichi Sankyo Company, Limited 16.7.1. Company Overview (HQ, Business Segments, Employee Strength) 16.7.2. Financial Overview 16.7.3. Product Portfolio 16.7.4. SWOT Analysis 16.7.5. Strategic Overview 16.8. Sanofi 16.8.1. Company Overview (HQ, Business Segments, Employee Strength) 16.8.2. Financial Overview 16.8.3. Product Portfolio 16.8.4. SWOT Analysis 16.8.5. Strategic Overview 16.9. Johnson & Johnson Services 16.9.1. Company Overview (HQ, Business Segments, Employee Strength) 16.9.2. Financial Overview 16.9.3. Product Portfolio 16.9.4. SWOT Analysis 16.9.5. Strategic Overview
Don't Need a Global Report?
save 40%! on Country & Region specific reports
List Of Table
Table 01: Global Anticoagulants Market Value (US$ Mn) Forecast, by Route of Administration, 2016–2031
Table 02: Global Anticoagulants Market Value (US$ Mn) Forecast, by Drug Class, 2016–2031
Table 03: Global Anticoagulants Market Value (US$ Mn) Forecast, by Indication, 2016–2031
Table 04: Global Anticoagulants Market Value (US$ Mn) Forecast, by Distribution Channel, 2016–2031
Table 05: Global Anticoagulants Market Size (US$ Mn) and Volume (Units) Forecast, by Region, 2021–2031
Table 06: North America Anticoagulants Market Value (US$ Mn) Forecast, by Country, 2016–2031
Table 07: North America Anticoagulants Market Value (US$ Mn) Forecast, by Route of Administration, 2016–2031
Table 08: North America Anticoagulants Market Value (US$ Mn) Forecast, by Drug Class, 2016–2031
Table 09: North America Anticoagulants Market Value (US$ Mn) Forecast, by Indication, 2016–2031
Table 10: North America Anticoagulants Market Value (US$ Mn) Forecast, by Distribution Channel, 2016–2031
Table 11: Europe Anticoagulants Size Value (US$ Mn) Forecast, by Country/Sub-region, 2016–2031
Table 12: Europe Anticoagulants Market Value (US$ Mn) Forecast, by Route of Administration, 2016–2031
Table 13: Europe Anticoagulants Market Value (US$ Mn) Forecast, by Drug Class, 2016–2031
Table 14: Europe Anticoagulants Market Value (US$ Mn) Forecast, by Indication, 2016–2031
Table 15: Europe Anticoagulants Market Value (US$ Mn) Forecast, by Distribution Channel, 2016–2031
Table 16: Asia Pacific Anticoagulants Size Value (US$ Mn) Forecast, by Country/Sub-region, 2016–2031
Table 17: Asia Pacific Anticoagulants Market Value (US$ Mn) Forecast, by Route of Administration, 2016–2031
Table 18: Asia Pacific Anticoagulants Market Value (US$ Mn) Forecast, by Drug Class, 2016–2031
Table 19: Asia Pacific Anticoagulants Market Value (US$ Mn) Forecast, by Indication, 2016–2031
Table 20: Asia Pacific Anticoagulants Market Value (US$ Mn) Forecast, by Distribution Channel, 2016–2031
Table 21: Latin America Anticoagulants Size Value (US$ Mn) Forecast, by Country/Sub-region, 2016–2031
Table 22: Latin America Anticoagulants Market Value (US$ Mn) Forecast, by Route of Administration, 2016–2031
Table 23: Latin America Anticoagulants Market Value (US$ Mn) Forecast, by Drug Class, 2016–2031
Table 24: Latin America Anticoagulants Market Value (US$ Mn) Forecast, by Indication, 2016–2031
Table 25: Latin America Anticoagulants Market Value (US$ Mn) Forecast, by Distribution Channel, 2016–2031
Table 26: Middle East & Africa Anticoagulants Size Value (US$ Mn) Forecast, by Country/Sub-region, 2016–2031
Table 27: Middle East & Africa Anticoagulants Market Value (US$ Mn) Forecast, by Route of Administration, 2016–2031
Table 28: Middle East & Africa Anticoagulants Market Value (US$ Mn) Forecast, by Drug Class, 2016–2031
Table 29: Middle East & Africa Anticoagulants Market Value (US$ Mn) Forecast, by Indication, 2016–2031
Table 30: Middle East & Africa Anticoagulants Market Value (US$ Mn) Forecast, by Distribution Channel, 2016–2031
More Insights, Lesser Cost (-50% off)
Insights on import/export production,
pricing analysis, and more – Only @ Fact.MR
List Of Figures
Figure 01: Global Anticoagulants Market Size Value (US$ Mn) Forecast, 2016–2031
Figure 02: Global Anticoagulants Market Value Share (%), by Route of Administration, 2021
Figure 03: Global Anticoagulants Market Value Share (%), by Drug Class, 2021
Figure 04: Global Anticoagulants Market Value Share (%), by End-user, 2021
Figure 05: Global Anticoagulants Market Value Share (%), by Region, 2021
Figure 06: Global Anticoagulants Market Value Share, by Route of Administration, 2021 and 2031
Figure 07: Global Anticoagulants Market Revenue (US$ Mn) and Y-o-Y Growth (%) Forecast, by Oral, 2016–2031
Figure 08: Global Anticoagulants Market Revenue (US$ Mn) and Y-o-Y Growth (%) Forecast, by Injectables, 2016–2031
Figure 09: Global Anticoagulants Market Attractiveness, by Route of Administration, 2021–2031
Figure 10: Global Anticoagulants Market Value Share, by Drug Class, 2021 and 2031
Figure 11: Global Anticoagulants Market Revenue (US$ Mn) and Y-o-Y Growth (%) Forecast, by Factor XA Inhibitors, 2016–2031
Figure 12: Global Anticoagulants Market Revenue (US$ Mn) and Y-o-Y Growth (%) Forecast, by Heparins, 2016–2031
Figure 13: Global Anticoagulants Market Revenue (US$ Mn) and Y-o-Y Growth (%) Forecast, by Direct Thrombin Inhibitors, 2016–2031
Figure 14: Global Anticoagulants Market Revenue (US$ Mn) and Y-o-Y Growth (%) Forecast, by Vitamin K Antagonists, 2016–2031
Figure 15: Global Anticoagulants Market Attractiveness, by Drug Class, 2021–2031
Figure 16: Global Anticoagulants Market Value Share, by Indication, 2021 and 2031
Figure 17: Global Anticoagulants Market Revenue (US$ Mn) and Y-o-Y Growth (%) Forecast, by Deep Vein Thrombosis (DVT), 2016–2031
Figure 18: Global Anticoagulants Market Revenue (US$ Mn) and Y-o-Y Growth (%) Forecast, by Pulmonary Embolism (PE), 2016–2031
Figure 19: Global Anticoagulants Market Revenue (US$ Mn) and Y-o-Y Growth (%) Forecast, by Atrial Fibrillation & Heart Attack, 2016–2031
Figure 20: Global Anticoagulants Market Revenue (US$ Mn) and Y-o-Y Growth (%) Forecast, by Others, 2016–2031
Figure 21: Global Anticoagulants Market Attractiveness, by Indication, 2021–2031
Figure 22: Global Anticoagulants Market Value Share, by Distribution Channel, 2021 and 2031
Figure 23: Global Anticoagulants Market Revenue (US$ Mn) and Y-o-Y Growth (%) Forecast, by Hospitals Pharmacies, 2016–2031
Figure 24: Global Anticoagulants Market Revenue (US$ Mn) and Y-o-Y Growth (%) Forecast, by Retail Pharmacies, 2016–2031
Figure 25: Global Anticoagulants Market Revenue (US$ Mn) and Y-o-Y Growth (%) Forecast, by Online Pharmacies, 2016–2031
Figure 26: Global Anticoagulants Market Attractiveness, by Distribution Channel, 2021–2031
Figure 27: Global Anticoagulants Market Value Share Analysis, by Region, 2021 and 2031
Figure 28: Global Anticoagulants Market Attractiveness Analysis, by Region, 2021 and 2031
Figure 29: North America Anticoagulants Market Value (US$ Mn) Forecast and Y-o-Y Growth Projection (%), 2016–2031
Figure 30: North America Anticoagulants Market Value Share, by Country, 2021 and 2031
Figure 31: North America Anticoagulants Market Attractiveness, by Country, 2021–2031
Figure 32: North America Anticoagulants Market Value Share, by Route of Administration, 2021 and 2031
Figure 33: North America Anticoagulants Market Attractiveness, by Route of Administration, 2021–2031
Figure 34: North America Anticoagulants Market Value Share, by Drug Class, 2021 and 2031
Figure 35: North America Anticoagulants Market Attractiveness, by Drug Class, 2021–2031
Figure 36: North America Anticoagulants Market Value Share, by Indication, 2021 and 2031
Figure 37: North America Anticoagulants Market Attractiveness, by Indication, 2021–2031
Figure 38: North America Anticoagulants Market Value Share, by Distribution Channel, 2021 and 2031
Figure 39: North America Anticoagulants Market Attractiveness, by Distribution Channel, 2021–2031
Figure 40: Europe Anticoagulants Market Value (US$ Mn) Forecast and Y-o-Y Growth Projection (%), 2016–2031
Figure 41: Europe Anticoagulants Market Value Share, by Country/Sub-region, 2021 and 2031
Figure 42: Europe Anticoagulants Market Attractiveness, by Country/Sub-region, 2021–2031
Figure 43: Europe Anticoagulants Market Value Share, by Route of Administration, 2021 and 2031
Figure 44: Europe Anticoagulants Market Attractiveness, by Route of Administration, 2021–2031
Figure 45: Europe Anticoagulants Market Value Share, by Drug Class, 2021 and 2031
Figure 46: Europe Anticoagulants Market Attractiveness, by Drug Class, 2021–2031
Figure 47: Europe Anticoagulants Market Value Share, by Indication, 2021 and 2031
Figure 48: Europe Anticoagulants Market Attractiveness, by Indication, 2021–2031
Figure 49: Europe Anticoagulants Market Value Share, by Distribution Channel, 2021 and 2031
Figure 50: Europe Anticoagulants Market Attractiveness, by Distribution Channel, 2021–2031
Figure 51: Asia Pacific Anticoagulants Market Value (US$ Mn) Forecast and Y-o-Y Growth Projection (%), 2016–2031
Figure 52: Asia Pacific Anticoagulants Market Value Share, by Country/Sub-region, 2021 and 2031
Figure 53: Asia Pacific Anticoagulants Market Attractiveness, by Country/Sub-region, 2021–2031
Figure 54: Asia Pacific Anticoagulants Market Value Share, by Route of Administration, 2021 and 2031
Figure 55: Asia Pacific Anticoagulants Market Attractiveness, by Route of Administration, 2021–2031
Figure 56: Asia Pacific Anticoagulants Market Value Share, by Drug Class, 2021 and 2031
Figure 57: Asia Pacific Anticoagulants Market Attractiveness, by Drug Class, 2021–2031
Figure 58: Asia Pacific Anticoagulants Market Value Share, by Indication, 2021 and 2031
Figure 59: Asia Pacific Anticoagulants Market Attractiveness, by Indication, 2021–2031
Figure 60: Asia Pacific Anticoagulants Market Value Share, by Distribution Channel, 2021 and 2031
Figure 61: Asia Pacific Anticoagulants Market Attractiveness, by Distribution Channel, 2021–2031
Figure 62: Latin America Anticoagulants Market Value (US$ Mn) Forecast and Y-o-Y Growth Projection (%), 2016–2031
Figure 63: Latin America Anticoagulants Market Value Share, by Country/Sub-region, 2021 and 2031
Figure 64: Latin America Anticoagulants Market Attractiveness, by Country/Sub-region, 2021–2031
Figure 65: Latin America Anticoagulants Market Value Share, by Route of Administration, 2021 and 2031
Figure 66: Latin America Anticoagulants Market Attractiveness, by Route of Administration, 2021–2031
Figure 67: Latin America Anticoagulants Market Value Share, by Drug Class, 2021 and 2031
Figure 68: Latin America Anticoagulants Market Attractiveness, by Drug Class, 2021–2031
Figure 69: Latin America Anticoagulants Market Value Share, by Indication, 2021 and 2031
Figure 70: Latin America Anticoagulants Market Attractiveness, by Indication, 2021–2031
Figure 71: Latin America Anticoagulants Market Value Share, by Distribution Channel, 2021 and 2031
Figure 72: Latin America Anticoagulants Market Attractiveness, by Distribution Channel, 2021–2031
Figure 73: Middle East & Africa Anticoagulants Market Value (US$ Mn) Forecast and Y-o-Y Growth Projection (%), 2016–2031
Figure 74: Middle East & Africa Anticoagulants Market Value Share, by Country/Sub-region, 2021 and 2031
Figure 75: Middle East & Africa Anticoagulants Market Attractiveness, by Country/Sub-region, 2021–2031
Figure 76: Middle East & Africa Anticoagulants Market Value Share, by Route of Administration, 2021 and 2031
Figure 77: Middle East & Africa Anticoagulants Market Attractiveness, by Route of Administration, 2021–2031
Figure 78: Middle East & Africa Anticoagulants Market Value Share, by Drug Class, 2021 and 2031
Figure 79: Middle East & Africa Anticoagulants Market Attractiveness, by Drug Class, 2021–2031
Figure 80: Middle East & Africa Anticoagulants Market Value Share, by Indication, 2021 and 2031
Figure 81: Middle East & Africa Anticoagulants Market Attractiveness, by Indication, 2021–2031
Figure 82: Middle East & Africa Anticoagulants Market Value Share, by Distribution Channel, 2021 and 2031
Figure 83: Middle East & Africa Anticoagulants Market Attractiveness, by Distribution Channel, 2021–2031
Know thy Competitors
Competitive landscape highlights only certain players
Complete list available upon request
- FAQs -
How much is the global anticoagulants market worth?
According to Fact.MR, the anticoagulants industry is expected to reach US$ 30 Bn in 2021.
What was the last 5 years CAGR for the anticoagulants industry?
From 2016 to 2020, Fact.MR estimated the market for anticoagulants soared at 5% CAGR
What is the anticipated future outlook for the anticoagulants landscape?
From 2021 to 2031, anticoagulants demand is expected to surge at a CAGR exceeding 8%
What is the most prevalent trend driving anticoagulants uptake?
Rising prevalence of atrial fibrillation and heart attacks is anticipated to increase uptake of anticoagulants
What is the U.S market outlook for anticoagulants?
Demand for anticoagulants in the U.S is expected to surge at a CAGR of 7.5% from 2021 to 2031
What is the growth outlook for the market in Japan?
Anticoagulants sales are expected to comprise 45% of the revenue share across Japan
How lucrative are growth prospects in China?
China is anticipated to register a growth rate of over 8% across the forthcoming decade
Which is the most preferred anticoagulant drug class?
NOAC/DOAC factor X-inhibitors are expected to be highly sought after, capturing 50% of total demand
Which is the most preferred distribution channel for anticoagulants?
Hospital pharmacies account for bulk of anticoagulants distribution, yielding 49.2% revenue
Anticoagulants Market